Handa Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,729	830.67	1,106	197.68	29.24
Revenue Growth (YoY)	108.17%	-24.92%	459.66%	576.16%	1.30%
Cost of Revenue	267.48	1.17	1.3	18.71	1.46
Gross Profit	1,462	829.5	1,105	178.97	27.77
Selling, General & Admin	165.02	119.54	144.25	87.31	72.67
Research & Development	362.57	291.91	267.34	179.78	208.99
Operating Expenses	527.59	411.44	411.59	267.09	281.66
Operating Income	934.18	418.06	693.43	-88.12	-253.88
Interest Expense	-2.2	-0.49	-0.22	-0.28	-0.23
Interest & Investment Income	59.21	57.06	18.16	0.5	0.29
Earnings From Equity Investments	0.29	-1.81	2.37	-	-
Currency Exchange Gain (Loss)	-	26.9	1.71	44.02	-7.27
Other Non Operating Income (Expenses)	-54.51	-20.36	0.03	0.73	0.27
EBT Excluding Unusual Items	936.98	479.36	715.47	-43.15	-260.82
Gain (Loss) on Sale of Assets	-	-0.19	4.61	-0	0.02
Legal Settlements	-	-	72.41	-	-
Pretax Income	936.98	479.17	792.49	-43.15	-260.8
Income Tax Expense	187.2	6.43	65.6	-3.14	-13.13
Net Income	749.77	472.74	726.89	-40.01	-247.67
Net Income to Common	749.77	472.74	726.89	-40.01	-247.67
Net Income Growth	58.60%	-34.96%	-	-	-
Shares Outstanding (Basic)	155	140	134	126	118
Shares Outstanding (Diluted)	155	141	135	126	118
Shares Change (YoY)	10.02%	4.73%	7.29%	6.65%	1.87%
EPS (Basic)	4.85	3.37	5.41	-0.32	-2.10
EPS (Diluted)	4.83	3.35	5.40	-0.32	-2.10
EPS Growth	44.18%	-37.96%	-	-	-
Free Cash Flow	226.72	489.84	667.42	-212.21	-184.82
Free Cash Flow Per Share	1.46	3.47	4.95	-1.69	-1.57
Dividend Per Share	2.000	1.500	1.000	-	-
Dividend Growth	33.33%	50.00%	-	-	-
Gross Margin	84.53%	99.86%	99.88%	90.53%	95.00%
Operating Margin	54.02%	50.33%	62.68%	-44.58%	-868.42%
Profit Margin	43.36%	56.91%	65.70%	-20.24%	-847.17%
Free Cash Flow Margin	13.11%	58.97%	60.33%	-107.35%	-632.19%
EBITDA	1,098	421.12	698.48	-81.3	-245.05
EBITDA Margin	63.51%	50.70%	63.14%	-41.13%	-
D&A For EBITDA	164.13	3.06	5.06	6.82	8.83
EBIT	934.18	418.06	693.43	-88.12	-253.88
EBIT Margin	54.02%	50.33%	62.68%	-44.58%	-
Effective Tax Rate	19.98%	1.34%	8.28%	-	-
Revenue as Reported	1,729	-	-	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.